Piramal Pharma
Piramal Pharma Share Price Chart
Piramal Pharma last traded at ₹197.25 (2026-10-13). Over the past month the stock moved -7.2%, three months the stock moved +10.3%, year the stock moved -2.2%. Its closing range over 52 weeks is ₹138.35 – ₹226.60, with the latest close 13.0% below the high.
Closing prices up to 2026-10-13.
About Piramal Pharma
Piramal Pharma Limited (PPL) is part of the Piramal group of companies. The company operates through 3 major segments (1) Contract development and manufacturing organisations (CDMO), (2) Complex hospital generics (critical care), and (3) consumer healthcare (OTC). Company entered Pharma space back in 1988 with acquisition of Nicholas Laboratories and grew through a series of Mergers & Acquisitions[1] and various organic initiatives. In 2010 the Domestic formulations business was sold to Abott for $3.7 billion[2] and Diagnostic Services was sold to Super Religare Laboratories (SRL)[3]
Business units [1] (1) Contract Development and Manufacturing Operations (CDMO) The company operates out of 15 CDMO sites with major presence in North America (4), Europe(2) and India (9). It is amongst the Top 3 CDMO players in India and the 13th largest globally. The company has ~500 CDMO customers as of FY24. [2] The company is targeting more integrated projects, 40% of their new orders in FY24 were for integrated projects. Revenue by Services[3] Other Commercial Manufacturing - 50% On-patent Commercial Manufacturing - 20% Development - 26% Discovery - 4% 84% of the revenues is earned from regulated markets like US, Europe and Japan. [4]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Piramal Pharma reported sales of ₹2,270.00 crore (+17.4%) and net profit of ₹-69.00 crore, compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 2,270 | 195.00 | 9.00 | -69.00 | -0.52 |
| Mar 2026 | 2,752 | 461.00 | 17.00 | -9.00 | -0.07 |
| Dec 2025 | 2,140 | 196.00 | 9.00 | -136.00 | -1.02 |
| Sep 2025 | 2,044 | 159.00 | 8.00 | -99.00 | -0.75 |
| Jun 2025 | 1,934 | 107.00 | 6.00 | -82.00 | -0.61 |
| Mar 2025 | 2,754 | 561.00 | 20.00 | 154.00 | 1.16 |
| Dec 2024 | 2,204 | 338.00 | 15.00 | 4.00 | 0.03 |
| Sep 2024 | 2,242 | 342.00 | 15.00 | 23.00 | 0.17 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +17.3% | +12.5% | +7.9% | -0.9% | -8.8% | -2.9% | -0.1% | +17.4% |
| Operating profit growth | +28.6% | +26.1% | +5.8% | -47.5% | -53.5% | -42.0% | -17.8% | +82.2% |
| Net profit growth | +360.0% | -60.0% | +52.5% | – | -530.4% | -3500.0% | -105.8% | – |
| EPS growth | +325.0% | -62.5% | +50.6% | – | -541.2% | -3500.0% | -106.0% | – |
| OPM % | 15.0% | 15.0% | 20.0% | 6.0% | 8.0% | 9.0% | 17.0% | 9.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Piramal Pharma reported sales of ₹8,869.00 crore (-3.1%) and net profit of ₹-326.00 crore (-458.2%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 8,869 | 922.00 | 10.00 | -326.00 | -2.45 |
| Mar 2025 | 9,151 | 1,445 | 16.00 | 91.00 | 0.69 |
| Mar 2024 | 8,171 | 1,197 | 15.00 | 18.00 | 0.13 |
| Mar 2023 | 7,082 | 629.00 | 9.00 | -186.00 | -1.41 |
| Mar 2022 | 6,559 | 950.00 | 14.00 | 376.00 | – |
| Mar 2021 | 6,315 | 1,428 | 23.00 | 835.00 | – |
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales growth | +3.9% | +8.0% | +15.4% | +12.0% | -3.1% |
| Operating profit growth | -33.5% | -33.8% | +90.3% | +20.7% | -36.2% |
| Net profit growth | -55.0% | -149.5% | – | +405.6% | -458.2% |
| EPS growth | – | – | – | +430.8% | -455.1% |
| OPM % | 14.0% | 9.0% | 15.0% | 16.0% | 10.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Piramal Pharma.
Get Free AI Stock Analysis FREE →Latest News
-
Piramal Pharma’s UK Facility Gets Seven Observations After US FDA Inspection
-
Piramal Pharma soars on completing acquisition of additional 40.67% stake in Yapan Bio
-
Piramal Pharma completes acquisition of additional 40.67% stake in Yapan Bio
-
Piramal Pharma soars on completing acquisition of additional 40.67% stake in Yapan Bio
-
Piramal Pharma Ltd soars 1.97%, up for third straight session - Business Standard
-
Piramal Pharma Ltd soars 1.97%, up for third straight session - business-standard.com
-
Piramal Pharma reports consolidated net loss of Rs 69.39 crore in the June 2026 quarter - Business Standard
-
Piramal Pharma reports consolidated net loss of Rs 69.39 crore in the June 2026 quarter - Business Standard
-
Piramal Pharma Ltd soars 0.83%, gains for fifth straight session - business-standard.com
-
Piramal Pharma Ltd soars 0.83%, gains for fifth straight session - business-standard.com
Frequently Asked Questions
What is the share price of Piramal Pharma today?
Piramal Pharma shares were last quoted at ₹197.25 (+0.2% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Piramal Pharma?
Piramal Pharma has a price-to-earnings (P/E) ratio of 39.96 and a price-to-book (P/B) ratio of 3.46. The industry P/E is 53.33.
What is the 52-week high and low of Piramal Pharma?
The 52-week high of Piramal Pharma is ₹231.85 and the 52-week low is ₹132.50.
What is the market cap of Piramal Pharma?
The market capitalisation of Piramal Pharma is about ₹27,984.94 crore.
How did Piramal Pharma perform in its latest quarterly results?
In the latest quarter (Jun 2026), Piramal Pharma reported sales of ₹2,270.00 crore (+17.4%) and net profit of ₹-69.00 crore, compared with the same quarter last year.
Is Piramal Pharma a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Piramal Pharma has a 3-year ROE of -1.00%, 3-year profit growth of -31.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Piramal Pharma?
Promoters hold about 34.80% of Piramal Pharma.
Which sector does Piramal Pharma belong to?
Piramal Pharma belongs to the Pharmaceuticals & Drugs sector.